Pacific Biometrics, Inc. Presents Amplification Technology at Experimental Biology 2003.
Business Editors & Health/Medical Writers
Experimental Biology 2003
SEATTLE--(BUSINESS WIRE)--April 25, 2003
Pacific Biometrics, Inc. (PBI PBI protein-bound iodine.
n See iodine, protein-bound.
protein-bound iodine. ) (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :PBME) announced today that it made its first public presentation of its proprietary DNA amplification technology (LIDA) at the Experimental Biology 2003 meeting in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation).
San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. .
PBI gave a presentation entitled "A novel isothermal i·so·ther·mal
Of, relating to, or indicating equal or constant temperatures.
having the same temperature. target amplification strategy based on deoxynucleotide-containing intermediate transcription products." The presentation was on PBI's Logarithmic Isothermal DNA Amplification (LIDA) technology. Highlights of the presentation included LIDA's speed, specificity, and use with real-time detection chemistries.
"Experimental Biology 2003 is the perfect place to present LIDA," commented Ron Helm, Chief Executive Officer at PBI. "This meeting represents an opportunity to showcase LIDA's abilities to a large international group of scientists and companies."
Experimental Biology 2003 was held from April 11-15 at the San Diego Convention Center The San Diego Convention Center is the main convention center for the city of San Diego, California. It is located in the Marina district of downtown San Diego near the Gaslamp Quarter, at 111 West Harbor Drive. and boasted over 12,000 scientists from all over the world. Contributions from the American Association of Anatomists, American Physiological Society, American Society for Biochemistry and Molecular Biology American Society for Biochemistry and Molecular Biology is an academic society founded in 1906. It is currently based on the campus of the Federation of American Societies for Experimental Biology in Bethesda, Maryland. , American Society for Investigative Pathology, American Society for Nutritional Sciences, American Society for Pharmacology and Experimental Therapeutics, and various guest societies rounded out the program.
About Pacific Biometrics, Inc.
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, osteoporosis, diabetes, and nutrition. The PBI laboratory is accredited accredited
recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria.
cattle herds which have achieved a low level of reactors to, e.g. by the College of American Pathologists This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. and is one of only five U.S.-based labs fully approved and accredited by the Center for Disease Control (CDC See Control Data, century date change and Back Orifice.
CDC - Control Data Corporation ) as a Cholesterol Reference Lab. Clients for PBI include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
As part of a recent asset purchase agreement with Saigene Corporation, Pacific Biometrics owns several patented and patent-pending technologies, including an advanced, proprietary, isothermal DNA amplification assay, and gene-based tests involved in sterility testing and antibiotic susceptibility testing.
For more information about Pacific Biometrics, visit the company's website at www.pacbio.com or contact Ronald Helm, Chairman/CEO at 206/298-0068.
Certain statements contained in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results and outcomes may differ materially from those discussed or anticipated. Factors that might affect the actual outcome include, but are not limited to, our problems of operating with a history of losses and an accumulated deficit, our potential liquidity problems since historically we have not been able to generate positive cash flow, our ability to raise additional capital and the likelihood that it may not be secured, our difficulties of competing in the biotechnology industry which is subject to rapid changes, our potential difficulties of protecting our patents and other proprietary rights and potential intellectual property claims against us, general competition and technological changes, the possible cancellation of our existing or future contracts, our future growth prospects, and changes in our management. For a more detailed discussion of risk factors, see the company's most recent documents filed with the Securities and Exchange Commission.